

**BISC/ImmPort Data Release 3 studies**

August 2013

**Note:** All studies packages have been updated to add new Study Category tables that highlight the Research Focus. For studies not listed below, there are no further changes.

**Study Program:** Influenza Pathogenesis & Immunology Research Center (IPIRC)**Title:** Serological Memory and Long-term Protection to Novel H1N1 Influenza Virus after Skin Vaccination**Accession:** SDY208**Subjects:** 7**Study PI, contact:** Joshy Jacob, Emory Vaccine Center, Emory University, Atlanta, GA**Study Description:** Skin vaccination in BALB/c mice with a single dose of 5 ug inactivated A/California/04/09 virus via coated metal microneedles (MN) applied to skin or via subcutaneous injection**Assays in ImmPort:**

Assay Type	Number of Exp. Samples
HAI	4
ELISA	61
ELISA	13
ELISPOT	9

**Clinical Assessments in ImmPort:** noneNotes: new study

---

**Study Program:** Vaccination and Infection: Indicators of Immunologic Health and Responsiveness**Title:** Apoptosis and other immune biomarkers predict influenza vaccine responsiveness**Accession:** SDY212**Subjects:** 91**Study PI, contact:** Mark M. Davis, Stanford University School of Medicine, Stanford, CA**Study Description:** In an effort to identify benchmarks of immunological health, influenza vaccination was used in 30 young (20 to 30 years) and 59 older subjects (60 to 89 years) as models for strong and weak immune responses, respectively.**Assays in ImmPort:**

Assay Type	Number of Exp. Samples
HAI	267
DNA Microarray	91
Peptide Microarray	91
PhosphoFlow	63
Flow Cytometry	540
MBAA, Luminex	91

**Clinical Assessments in ImmPort:** noneNotes: new study

---

**Study Program:** Vaccination and Infection: Indicators of Immunologic Health and Responsiveness**Title:** Vaccination of CD95-/- mice and ELISA for detection of influenza-specific antibodies

**Accession:** SDY215

**Subjects:** 17

**Study PI, contact:** Mark M. Davis, Stanford University School of Medicine, Stanford, CA

**Study Description:** Evaluation of influenza vaccination immune response in mice

**Assays in ImmPort:**

Assay Type	Number of Exp. Samples
ELISA	101

**Clinical Assessments in ImmPort:** none

Notes: new study

---

**Study Program:** New York Influenza Center of Excellence

**Title:** Antigenic and immunogenic properties of recombinant hemagglutinin proteins when produced in various protein expression systems

**Accession:** SDY78

**Subjects:** 178

**Study PI, contact:** David J. Topham, New York Influenza Center of Excellence, Rochester, NY

**Study Description:** Binding of anti-HA specific antibodies, elicited by vaccination or viral infection, to various recombinant forms of the HA from A/Brisbane/59/07 and B/Florida/04/06

**Assays in ImmPort:**

Assay Type	Number of Exp. Samples
ELISPOT	52
ELISA	115
HAI	64
HAI	90
ELISPOT	8
ELISA	96
ELISA	44

**Clinical Assessments in ImmPort:** none

Notes: new study

---

**Study Program:** New York Influenza Center of Excellence

**Title:** CD4 T cell response to pH1N1 vaccination

**Accession:** SDY97

**Subjects:** 49

**Study PI, contact:** Andrea Sant, University of Rochester Medical Center, Rochester, NY

**Study Description:** Healthy adult human subjects were given monovalent inactivated pH1N1 vaccine and antibody responses were assessed using HAI and MN assays. CD4 T cell reactivity was examined using IFN gamma Elispot assays to look at reactivity to unique and conserved peptide pools.

**Assays in ImmPort:**

Assay Type	Number of Exp. Samples
ELISPOT	950
HAI	194
Virus Neutralization	194

**Clinical Assessments in ImmPort:** none

Notes: new study

---

**Study Program:** Immunobiology of Food Allergy and its Treatment (CoFAR)

**Title:** Oral Immunotherapy for Childhood Egg Allergy

**Accession:** SDY218

**Subjects:** 55

**Study PI, contact:** Wesley Burks, Duke University Medical Center, Durham, NC

**Study Description:** The purpose of this study is to determine the safety and efficacy of the administration of oral immunotherapy (OIT). The intent is to develop desensitization and eventually tolerance to egg allergen.

**Assays in ImmPort:**

Assay Type	Number of Exp. Samples
none	

**Clinical Assessments in ImmPort:** Adverse Events, Atopic Dermatitis, Basophil, Medication, Protocol Deviation, Study Encounter, Initial Escalation, Food Allergy Episode, Antibody Assay, Baseline Medical History, Prick Skin Results, Visit Form, Study Product Tracking

**Notes:** new study

---

**Study Program:** Influenza Pathogenesis & Immunology Research Center (IPIRC)

**Title:** Systems Biology of Seasonal Influenza Vaccination in Humans

**Accession:** SDY61

**Subjects:** 113

**Study PI, contact:** Bali Pulendran, Emory Vaccine Center, Atlanta, GA

**Study Description:** Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during 3 consecutive influenza seasons

**Assays in ImmPort:**

Assay Type	Number of Exp. Samples
HAI	390
ELISPOT	336
FCM	63
MBAA	168
Array	290
Q-PCR	196
ELISA	100
Immunoblot	10
Immunoblot	16

**Clinical Assessments in ImmPort:** none

**Notes:** update of subject to ARM mapping

---

**Study Program:** Influenza Pathogenesis & Immunology Research Center (IPIRC)

**Title:** Immunologic and genomic signatures of response to Hepatitis C Virus Infection

**Accession:** SDY162

**Subjects:** 20

**Study PI, contact:** David Hafler, Yale University, New Haven, CT

**Study Description:** Examine the immune response in primary immune cells from subjects who have spontaneously cleared HCV compared to HCV chronically infected subjects

**Assays in ImmPort:**

Assay Type	Number of Exp. Samples
Array	80

**Clinical Assessments in ImmPort:** none

Notes: Updated treatment information for HCV microarray data

---

**Study Program:** Population Genetics Analysis Programs: Immunity to Vaccines/Infections

**Title:** Genetic Associations in subjects of anthrax trial [Anthrax Vaccine Adsorbed: Human Reactogenicity and Immunogenicity Trial to Address Change in Route of Administration and Dose Reduction (AVA000)]

**Accession:** SDY24

**Subjects:** 1563

**Study PI, contact:** Richard Kaslow, University of Alabama, Birmingham, AL

**Study Description:** Innate immunity gene products are known to be the first-line of host-defense and to control and assist the adaptive immune system. This research represents the opportunity to study, in detail, the responses longitudinally to vaccination (using clinical examination and laboratory assays) in a large ethnic population. Consequently, a prioritized set of genes and gene products from both systems will be evaluated

**Assays in ImmPort:**

Assay Type	Number of Exp. Samples
ELISA	35092
HLA typing	949
Array	1
Sequencing	2

**Clinical Assessments in ImmPort:** none

Notes: added ELISA experiment to view

---

**Study Program:** Population Genetics Analysis Program: Immunity to Vaccines/Infection

**Title:** Genotyping and gene functions in healthy volunteers

**Accession:** SDY25

**Subjects:** 1426

**Study PI, contact:** Richard Kaslow, University of Alabama, Birmingham, AL

**Study Description:** Functionally important genetic variants (certain naturally occurring SNPs) in a set of candidate genes that are known to be relevant for immune response to protein antigens, are expected to be associated with AbPA response and B-cell physiology.

**Assays in ImmPort:**

Assay Type	Number of Exp. Samples
none	

**Clinical Assessments in ImmPort:** Serum cytokine/chemokine quantification, serum immunoglobulin

Notes: Updates to subject-to-arm mapping

---

**Study Program:** Population Genetics Analysis Programs: Immunity to Vaccines/Infections

**Title:** Humoral and Cell-Mediated Immune Responses to Vaccinia Virus Immunization

**Accession:** SDY28

**Subjects:** 1092

**Study PI, contact:** Gregory Poland, Mayo Clinic, Rochester, MN

**Study Description:** Our broad objective is to examine the role of candidate human immune response gene polymorphisms (and their receptors, expression and function) in inter-individual variability in

vaccinia vaccine-induced humoral and cell-mediated immune responses among a cohort of 1,000 vaccinated subjects.

**Assays in ImmPort:**

Assay Type	Number of Exp. Samples
ELISPOT	13819
ELISPOT	13420
HLA Typing	1071
Genotyping	1
ELISA	4317
ELISA	66791
Array	426
Genotyping	341
Genotyping	339
Flow Cytometry	806

**Clinical Assessments in ImmPort:**

Notes: Shared two additional experiments--genotyping

---

**Study Program:** New York Influenza Center of Excellence

**Title:** Vaccination with drifted variants of H5 hemagglutinin protein elicits a broadened antibody response

**Accession:** SDY62

**Subjects:** 86

**Study PI, contact:** Felix Santiago, University of Rochester Medical Center, Rochester, NY

**Study Description:** Assess the humoral response of mice immunized with drifted variant H5 hemagglutinin proteins

**Assays in ImmPort:**

Assay Type	Number of Exp. Samples
Virus Neutralization	66
ELISA	108

**Clinical Assessments in ImmPort:** none

Notes: added competitive ELISA to view, added schematic placeholder

---

**Study Program:** NIAID Vaccine Research Center (VRC)

**Title:** A Phase I Study of the Safety and Immunogenicity of a Recombinant DNA Plasmid Vaccine (VRC-AVIDNA036-00-VP) Encoding for the Influenza Virus H5 Hemagglutinin Protein in Healthy Adults

**Accession:** SDY167

**Subjects:** 45

**Study PI, contact:** Julie Ledgerwood, NIAID, Vaccine Research Center, Bethesda, MD

**Study Description:** VRC304 - A Phase I, double-blind, placebo-controlled, randomized, dose escalation study to evaluate safety, tolerability, and immunogenicity of a recombinant DNA vaccine against the influenza virus hemagglutinin H5.

**Assays in ImmPort:**

Assay Type	Number of Exp. Samples
ELISA	430
HAI	44
ELISPOT	300

Virus Neutralization	88
----------------------	----

**Clinical Assessments in ImmPort:** Actual Visit, Adverse Event, Chemistry, Hematology, Report Early Termination

Notes: Updated to add FCS files

---